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Objectives: Analyses of drug cost-effectiveness have traditionally been based 
on two key components: effectiveness measured by clinical endpoints reported 
in product label or biomedical literature, and cost obtained from available pricing 
sources. While the former is a relatively well-defined value derived from pivotal 
trials and subsequent studies, the latter has often not been well-described or rigor-
ously assessed, and may be based upon manufacturer-reported pricing information 
that has been shown to be inaccurate and unreliable. This study examines existing 
benchmarks against newly available sources of pharmaceutical pricing, describes 
their interrelationships and assesses their stability over time. MethOds: Using 
publicly available cost data for wholesale acquisition cost (WAC), average manu-
facturer price (AMP), national average drug acquisition cost (NADAC), AMP-based 
federal upper limit (FUL), and a composite of six states’ average acquisition cost 
(AAC), mean, median, and standard deviation values were calculated for a broad 
range of pharmaceuticals and trade classes (brand vs. generic) and analyzed tem-
porally for trend and consistency patterns. Results: Available pricing data reflects 
an extremely high degree of variability and inconsistent relationships, both between 
equivalent products and from one price type to another. Generic drug prices demon-
strated the greatest irregularity, and although the ratio of NADAC or AMP to WAC for 
branded drugs showed correlations overall, for given products those relationships 
could be substantially at variance. cOnclusiOns: Continuing review and analysis 
of all available price types is needed to identify a reliable drug pricing benchmark 
that permits reviewers and clinicians to determine the optimal course of treatment. 
Since reported ratios may shift over time, future reports of cost-effectiveness must 
explicitly identify the cost basis employed and its reliability for the products at issue.
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Objectives: Head-to-head randomized controlled trials (RCTs) remain the gold 
standard for establishing relative treatment efficacy and for use in cost-effective-
ness (CE) models. However, in some cases, such as rare diseases, only single-arm 
trials may be available. We identified health technology appraisals (HTAs) published 
by the National Institute for Health and Care Excellence (NICE) that included evi-
dence from single-arm trials and reviewed the use of the single-arm trial data in 
accompanying CE models. MethOds: We searched the NICE website for published 
technology appraisals using the term “single-arm”. We reviewed HTAs in which 
single-arm trials were used and recorded the date of the appraisal, disease area, use 
of the single-arm trial data, the NICE recommendation, and NICE’s comments on 
the use of the single-arm trials. Results: Twenty-two HTAs included a reference 
to one or more single-arm trials. Fourteen provided the single-arm trial data only 
as supporting evidence to at least one RCT. Of the eight that used single-arm trial 
data, all also used the data in a model; four used the data as the primary evidence of 
efficacy, two used the data to extend an RCT, and two used the data for other inputs. 
Only one of the four using the data for evidence of efficacy resulted in a positive 
recommendation from NICE. In this case, evidence was from seven single arm trials; 
two manufacturer models and the assessment group model all demonstrated the 
intervention to be dominant over standard care, and several other factors may have 
contributed to a positive recommendation. In the three HTAs resulting in a negative 
recommendation, NICE expressed concerns over the efficacy data. cOnclusiOns: 
Although RCTs are preferred for relative efficacy data for use in cost-effectiveness 
analyses in NICE HTAs, there is one case of a positive NICE recommendation despite 
efficacy evidence being based on single-arm trials.
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Objectives: Efficiency may be crucial to a health technology’s value proposition. 
Measuring time endpoints prospectively is subject to variability and bias that 
makes Time and Motion (T&M) methodology complex. The aim was to investi-
gate key design characteristics of T&M studies recently presented at ISPOR con-
ferences. MethOds: A search was performed in ScienceDirect, using “time and 
motion” as key term, restricted to ‘Value in Health’ journal for the years 2008-2013 
to identify all ISPOR conference presentations during that period. Presentations 
were excluded based on the following criteria: (1) not a T&M study; (2) not present-
ing T&M results. Results: Of 116 abstracts, 29 complied with inclusion criteria; 8 
presentations could not be obtained; 7 were later excluded; 14 were retained for 
detailed assessment: 11 were observational studies, 2 reported survey data, and 1 
was a simulation study. Distribution of interventions being studied was: drug (43%), 
medical supply (29%), device (14%), and procedure (14%). 64% were conducted in 
Europe and 43% were multi-country. Primary objective of 13 studies was measuring 
process time (one only focused on cost); 57% also reported cost results. 13 studies 
measured time for tasks composing a process in a hospital setting with number 
of tasks ranging from 2 to 8; one study measured HCP workload. 85% investigated 
two processes (15% 3-4), but none were comparative studies powered to test a 
hypotheses of time differences between groups. 43% reported inferential statistics 
(e.g. covariance analyses, 95% CIs). One study applied a multilevel model to test 
centre clustering. cOnclusiOns: This T&M study review reveals a clear choice for 
descriptive non-hypotheses testing designs; some employ inferential statistics. In 
multi-centre studies, multilevel models to account for “centre clustering” are scarce. 
sions have been reached. This study sought to assess the relationship between 
Body Mass Index (BMI) and health care costs using 2006-2010 data from the Medical 
Expenditure Panel Survey (MEPS). MethOds: Eligible patients were ≥ 18 years, with 
a diabetes diagnosis (CCC-250) and on at least one oral antidiabetic medication. 
Primary outcomes were: 1) diabetes-related direct medical costs, 2) all-cause direct 
medical costs, and 3) indirect costs. Costs were inflated to 2010 US dollars using the 
medical consumer price index. The main independent variable was BMI, categorized 
as normal weight BMI: 18.0-24.9; overweight BMI: 25.0-29.9; obese BMI: 30.0-40.0; 
and morbidly obese BMI: > 40.0 kg/m2. Covariates included demographic and clinical 
variables. Generalized linear models with gamma distribution and log link function 
were conducted. Results: A final unweighted sample size of 7,003 patients was 
obtained (14.6 million weighted), with a mean age (±SE) = 61.2 (±0.2) years, mean BMI 
(±SE) = 32.2 (±0.1), and 50.4% were males. After controlling for covariates, diabetes-
related direct medical costs of normal-weight patients ($1,622) were lower than their 
overweight ($1,955; p= 0.031), obese ($2,259; p= 0.001) and morbidly obese ($2,636; 
p= 0.003) peers. But direct all-cause medical costs of overweight patients were less 
($9,715; p= 0.021) compared to normal weight ($11,623) patients. All-cause direct 
costs for obese ($11,419) and morbidly obese ($13,043) patients were not statisti-
cally different than costs for normal weight peers. Indirect costs (estimated as lost 
productivity) were similar between all 4 cohorts ($532-$535). cOnclusiOns: Being 
overweight (BMI = 25.0 to 29.9 kg/m2) was associated with higher diabetes-related 
direct medical costs, but lower all-cause direct medical costs compared to their 
normal weight peers.
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Objectives: The aim of the study is to assess the long-term economic value of one 
additional child born in Hungary, Italy, Spain, Sweden and the UK. MethOds: Two 
different methodologies are applied. The Human Capital Approach representing 
the perspective of the society is used to estimate the potential loss in production 
for every unborn child. It is calculated by summing up the discounted value of 
all expected future gross earnings of the individual, including an imputed value 
for household production. The Lifetime Investment Approach representing the 
point of view of the government is used to calculate the impact of an additional 
child on the fiscal balance. Expected revenues from taxes and social contributions 
and expected public expenditures (e.g. education, health, pension, etc.) for the 
lifetime of average person are calculated. The net balance is discounted to obtain 
the present value. Input data is obtained from the statistical databases of the 
OECD and EUROSTAT and from own calculations. Results are presented as a per-
centage of GDP per capita for 2012. Results: Preliminary results indicate that 
there is great heterogeneity between countries in the values of one additional 
child born. The present value of future earnings according to the Human Capital 
Approach indicates that a child will produce 11 to 21 times the 2012 GDP per 
capita during his lifetime. According to the Lifetime Investment Approach, an 
average child will contribute 3.4 and 6.0 times the GDP per capita of government 
revenues by the end of his lifetime. cOnclusiOns: The two methods used pre-
sent gains (or losses) of an additional child from the perspective of the society 
as well as from the point of view of the sustainability of public finances. Results 
vary by country. Therefore, it is essential that such calculations are performed on 
a country-by-country bases.
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Objectives: To use baseline results from a prospective observational study in 
Alzheimer’s disease (AD) to evaluate methods for dealing with missing longi-
tudinal AD cost data. MethOds: GERAS is an 18-month observational study of 
costs associated with AD. Total societal costs included patient health care costs 
(including hospitalizations, outpatient visits, and medication) and social care costs 
(including home-care and day-center sessions), and caregiver informal care costs 
(from time spend on informal care). Missing longitudinal cost data due to patient 
death/institutionalization was classified as not missing at random (NMAR). Cost 
data missing for other reasons was classified as missing at random (MAR) or 
missing completely at random (MCAR). To assess the impact of imputing missing 
longitudinal cost data, patterns of missing data during follow-up were simulated 
based on baseline GERAS data to generate 10%, 20%, 30% and 40% missing data for 
MCAR, MAR and NMAR classifications. Naïve methods (including complete case 
analysis, mean imputation and regression models), multiple imputation (MI) and 
a fixed cost were applied to each dataset and %bias assessed using (estimated-
actual)/actual cost*100. Results: Total baseline societal costs were available for 
1488 (99.4%) of enrolled patients, with a mean monthly cost of € 2101(95% CI: 
€ 1980-€ 2222). For MCAR datasets, naïve methods performed as well as MI (20% 
missing data: 0.6-10.9% bias naïve methods vs 0.2-6.1% MI). For MAR data, MI 
methods performed better (-3.2% to -14.3% bias) than naïve methods (6.6%-18.0% 
bias). All approaches were consistently poor with NMAR data (bias range -31.4% to 
-38.6%); the best performing approach was to impute a fixed value (monthly cost 
of institutionalisation) with -22.6% bias. For all approaches %bias increased with 
missing data volume. cOnclusiOns: Methods used to impute missing cost data 
in AD should be tailored depending on the type of missing data, using sensitivity 
analysis to assess the impact of any assumptions.
